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Tumor formation is a complex process that occurs in different steps and involves many cell
types, including tumor cells, endothelial cells, and inflammatory cells, which interact to pro-
mote growth of the tumor mass and metastasization. Epigenetic alterations occurring in
transformed cells result in de-regulation of miRNA expression (a class of small non-coding
RNA that regulates multiple functions), which contributes to tumorigenesis. The specific
miRNAs, which have an aberrant expression in tumors, are defined as oncomiRNAs, and
may be either over- or under-expressed, but down-regulation is most commonly observed.
Renal cell carcinoma (RCC) is a frequent form of urologic tumor, associated with an alter-
ation of multiple signaling pathways. Many molecules involved in the progression of RCCs,
such as HIF, VEGF, or mammalian target of rapamycin, are possible targets of de-regulated
miRNAs. Within tumor mass, the cancer stem cell (CSC) population is a fundamental com-
ponent that promotes tumor growth. The CSC hypothesis postulates that CSCs have the
unique ability to self-renew and to maintain tumor growth and metastasis. CSCs present in
RCC were shown to express the mesenchymal stem cell marker CD105 and to exhibit self-
renewal and clonogenic properties, as well as the ability to generate serially transplantable
tumors.The phenotype of CSC has been related to the potential to undergo the epithelial–
mesenchymal transition, which has been linked to the expression pattern of tumorigenic
miRNAs or down-regulation of anti-tumor miRNAs. In addition, the pattern of circulating
miRNAs may allow discrimination between healthy and tumor patients.Therefore, a miRNA
signature may be used as a tumor biomarker for cancer diagnosis, as well as to classify
the risk of relapse and metastasis, and for a guide for therapy.
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OncomiRNAs
miRNAs are a class of small non-coding RNAs involved in multiple
biological processes. Generation of mature miRNAs requires sev-
eral steps. Pri-miRNA is the first inactive form produced within the
nucleus. Pri-miRNA forms a stem-loop structure recognized by a
protein complex, composed of DGCR8 and Drosha enzyme. This
protein complex processes the pri-miRNA into a double-stranded
hairpin structure of approximately 70 nucleotides, which is called
precursor miRNA (pre-miRNA) (1, 2). These initial steps all take
place in the nucleus, followed by exportation of the pre-miRNA to
the cytoplasm in a GTP-dependent manner, mediated by another
protein complex, Exportin-5 bound to Ran (3). In the cytoplasm,
the pre-miRNA is further processed to generate a dsRNA by the
RNase III enzyme, Dicer. One of the two strands that are gen-
erated, known as passenger miRNA or miRNA*, is degraded. The
remaining mature single-stranded (ss) miRNA, associates with the
RNA-induced silencing complex (RISC). The resulting complex
is then able to bind the 3′-untranslated region (3′-UTR) on the
target mRNA.
miRNAs interact with the region recognized in the mRNA
sequence, by two to eight nucleotides present at the 5′ end of
the miRNA. This region is called the seed sequence and deter-
mines the specificity of the interaction with the mRNA at its
3′-UTR (4). If the miRNA/mRNA interaction is precise, the mRNA
is immediately degraded by Ago2, a protein of the argonaute
family. Conversely, if there is no precise interaction, a translational
repression of the mRNA occurs (4).
Abnormally expressed miRNAs in cancer are called oncomiR-
NAs. Numerous evidence correlates miRNA de-regulation with
tumor stages, types, and progression. The epigenetic alterations
that usually take place in a transformed cell, are probably respon-
sible for the miRNA de-regulation observed in cancer (5). miRNA
expression and cancer progression are usually inversely correlated.
Indeed, an overall down-regulation of miRNAs is usually observed
in tumor cells, although there may also be a small group of pro-
oncogenic miRNAs that is up-regulated. Recently, the possible
therapeutic use of miRNAs has been evaluated. This may include
miRNA replacement therapies for tumor-suppressor-miRNAs,
and inhibition strategies for oncogenic miRNAs (5).
CANCER STEM CELLS AND OncomiRNAs
The cancer stem cell (CSC) hypothesis postulates that there is
a rare subpopulation of cancer cells that possesses the ability to
self-renew and sustain tumor growth and metastasis. CSCs divide
asymmetrically, generating one identical daughter cell and one cell
that starts to differentiate and divide (6). The presence of CSCs was
first described in 1997 by Bonnet and colleagues (7), who identi-
fied CSCs in acute myeloid leukemia. Subsequently, in 2003, CSCs
were also isolated in breast cancer by Al-Hajj et al. (8), using the
specific cell surface markers, CD44 and CD24. Thereafter, CD133,
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CD166, and EpCAM, along with other surface markers, were also
used to isolate CSCs in many tumors (9). During the last decade,
CSCs were identified in numerous solid tumors, such as ovary,
brain, pancreatic, prostate, colon, melanomas, and hepatocellu-
lar cancers (6). Functional criteria for CSC identification include
clonogenicity and the ability to generate serially transplantable
tumors, starting from a very low number of cells (10).
miRNAs may regulate the properties of CSCs by acting on sev-
eral different signaling pathways. The progression from a stem
cell to a terminally differentiated cell depends on a temporal bal-
ance between proliferation and differentiation programs. This
balance is altered in tumors, partly as consequence of miRNA
de-regulation, leading to the maintenance of proliferation and self-
renewal of CSCs (11). miRNAs are divided in two categories based
on their effect on stem cell phenotype, namely miRNAs that play a
role in pluripotency, and miRNAs involved in differentiation. The
first group controls the capacity of self-renewal and cell division,
and inhibits the differentiation of stem cells. miR-184, -137, -290,
-302, -200, and -9 all belong to this class (12). On the other hand,
miRNAs that promote differentiation are let-7, miR-134, -122, -
181, -145, -296, and -470 (12). miR-134, -296, and -470 suppress
the self-renewal ability of CSCs by targeting some of the main mol-
ecules involved in the stem cell phenotype, such as Oct-4, Nanog,
and Sox2 (12).
The first evidence that miRNA expression was down-regulated
in CSCs was shown in breast CSCs. Yu et al. demonstrated the
decrease of let-7, miR-16, -107, -128, -20b and of all the members
of the miR-200 family (13). Within this group of miRNAs, the
main miRNA involved in the suppression of CSC self-renewal was
shown to be let-7 (12).
Let-7 is a ubiquitously expressed family that has been highly
conserved through evolution, suggesting a pivotal role for these
miRNAs in the regulation of proliferation and differentiation;
this family was one of the first mammalian groups of miRNAs
ever discovered (14). Let-7 miRNAs are regulators of cell cycle
exit and differentiation, and their targets are cell cycle modula-
tors, such as CDC25A and CDK6 and different early embryonic
genes (14, 15). There is a reduced expression of let-7 miRNAs in
CSCs of different tissues, such as gastric and breast carcinomas
(13, 16). Over-expression of this family in tumor cells was shown
to induce reduction of tumor progression and inhibition of stem-
ness properties (17). Moreover, let-7 members have been classified
as negative regulators of the epithelial-to-mesenchymal transition
(EMT) (17).
Of those miRNAs defined as tumorigenic, miR-21 plays an
important role. An increased expression of miR-21 was observed
in many tumors, including prostate, brain, breast, and pancreatic
cancer, and correlates with a poor patient prognosis (18).
Another family of miRNAs that is often down-regulated during
cancer progression is miR-200 and is composed of five members
(miR-200a, -200b, -200c, -141, and -429). miR-200a, b, and c are
significantly decreased in CSCs derived from human and murine
breast cancer (19).
Despite the huge number of miRNAs that are commonly altered
during tumor development, some of them are considered to be
tumor specific. For example, miR-22 acts as a tumor suppressor
during liver carcinogenesis, and its down-regulation is associated
with a poor clinical outcome. Experimental results have shown
that the over-expression of miR-22 leads to a reduction of tumor
cell invasion and growth affecting p53, p21, and PTEN (17). In
addition, CSCs from hepatocellular carcinoma are characterized
by the up-regulation of miR-92, -93, -181 family, -17, -20a, -25,
and -106b (20).
miR-101, -26, and -34a are additional examples of miRNAs
with tumor suppressor functions, and are down-regulated in many
solid cancers, including hepatic, pancreatic, lung, and prostate
cancers (17).
Recent studies have suggested a connection between CSCs
and the EMT. The EMT is an evolutionary-conserved biological
process whereby epithelial cells acquire mesenchymal characteris-
tics, and is involved in apoptosis resistance, tumor motility, and
invasion. Molecules associated with this process are transcrip-
tion factors, such as ZEB (ZEB1 and 2), Snail, Slug, and Twist1,
which act by repressing E-cadherin and inducing vimentin and
fibronectin expression (21). The EMT process is strongly regu-
lated by miRNAs; for example, the miR-106b-25 cluster has been
shown to induce the EMT and CSC phenotype in human breast
cancer cells, acting downstream of the transcription factor Six1. A
direct target of this miRNA family is the Smad7 protein; reduction
of Smad7 leads to activation of TGFβ signaling, which regulates
the EMT (22). Mani et al. (23) recently demonstrated the down-
regulation of miR-203 in CSCs that were undergoing the EMT
(23). Re-expression of miR-203 compromises the cell migratory
and invasive capacity in vitro and tumor initiation and metastasis
in vivo.
ROLE OF miRNAs IN METASTASIS
Metastasization is a tumor-specific mechanism divided into differ-
ent steps. Tumor cells invade the extracellular cell matrix (ECM) in
order to access the blood fluid, after which they extravasate at dis-
tant sites where they form secondary tumors. The role of miRNAs
in the acquisition of metastatic phenotypes has been well estab-
lished. miRNAs involved in metastasization are either classified as
metastasis-suppressive or metastasis-promoting miRNAs (24).
The first event that occurs in metastasization is the enhanced
capability of tumor cells to invade the ECM through destruction
of ECM proteins, and regulation of this process is carried out by
metastasis-promoting miRNAs. The invasive potential of prostate
cancer cells has been shown to be controlled by miR-21, which
targets MARCKS, involved in cell motility (25). Moreover, miR-21
has been associated with tumor cell invasion and metastasization
in colorectal and breast cancers, where it targets tumor suppressor
PDCD4 at a post-transcriptional level (26). In addition, miR-21
has been correlated with the ability of glioma cells to migrate and
invade, as a consequence of modulation of the metalloproteinase
inhibitors, RECK and TIMP3 (27).
Another example of a metastasis-promoting miRNA is miR-
10b, which has been described as a metastatic promoter in breast
cancer cells. miR-10b down-regulates the metastatic suppressive
gene, homeobox D10, which in turn inhibits the metastasis-
promoting gene RHOC (28). miR-373 and -520c, which belong
to the same family as miR-10b, have also been classified as pro-
metastasis miRNAs (29). The target of this particular miRNA
family was found to be CD44, and its down-regulation has been
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associated with the acquisition of an enhanced migratory potential
(29). Similarly, miR-182 over-expression promotes migration and
invasion in melanoma cells (30). miR-30b/30d also correlates with
tumor melanoma progression via down-regulation of GALNT1
and GALNT7, which are suppressors of cell invasion (31). In addi-
tion, miR-126 and -183 over-expression has been observed to be
involved in the metastasization of lung cancer (32, 33).
Metastasis-suppressive miRNAs (24) were first identified in
breast cancer cells (34). Over-expression of miR-335, -126, and
-206 was shown to block the ability of tumor cells to invade
and generate metastasis in bone and lungs (34). On the contrary,
down-regulation of miR-335 by antagomirs enhances metastasis
formation (34), and miR-335 plays a regulatory role in the expres-
sion of a set of metastatic genes, such as Tenascin-C and SOX4
(35, 36). On the other hand, miR-126 acts principally to inhibit
tumor growth, endothelial activation, and metastatic initiation
(37, 38), whilst miR-31 has been described to inhibit cancer pro-
gression and metastasization in breast tumors (39). The cohort of
pro-metastatic target genes affected by miR-31 expression includes
Integrin-alpha V, RDX, and RHOA, all involved in cell migration
(40). Another metastasis-suppressive miRNA, miR-146b, which
targets the matrix metalloproteinase 16, was shown to reduce the
invasion potential of glioblastoma U373 cells (41). miR-205, has
also been shown to promote E-cadherin expression and reduction
of prostate cancer cell migration and invasion (42).
CIRCULATING TUMOR-DERIVED miRNAs
Circulating RNAs in body fluids were first described in 1972
by Kamm and Smith (43). Circulating miRNAs in body fluids
are present as either vesicle-encapsulated or non-encapsulated.
Extracellular vesicles (EVs) are circular membrane fragments of
different origins that retain characteristics of the cell of origin, and
contain biological materials (lipids, proteins, and genetic infor-
mation) (44). EVs are described as a mechanism for cell-to-cell
communication, capable of influencing the phenotype of target
cells. The EV signaling mechanism can occur by different ways,
for example, direct stimulation via surface-receptors, or transfer
of proteins or genetic materials, such as mRNAs and miRNAs (45).
Many authors have described the presence of miRNAs in biolog-
ical fluids that are contained within EVs, and confer resistance
to RNAse activity and persistence within the circulation (46–48).
Non-encapsulated miRNAs that are present in serum and plasma
are associated with proteins such as lipoproteins and Ago fam-
ily proteins (49–51). It was recently discovered that miRNAs are
present at high levels in the blood stream of cancer patients (47,
52). The detection and characterization of circulating miRNAs
can be a powerful tool for non-invasive diagnosis of different can-
cers (53–55). Lawrie et al. (52) described circulating miRNAs in
the serum of B-cell lymphoma patients, and they were able to
discriminate between healthy controls and patients with tumors
by screening for three tumor-associated miRNAs (miR-155, -210,
and -21).
Further investigations into the presence of circulating miR-
NAs were carried out by Mitchell et al. (47), using a prostate
tumor xenograft mouse model. They observed that human miR-
NAs are detectable in the bloodstream when the tumor is well
established. By screening a list of candidate miRNAs present in the
plasma, the authors proposed miR-141 as a prostate cancer bio-
marker, and by analyzing miR-141 expression, they were able to
distinguish between healthy controls and advanced prostate cancer
patients.
In a recent study, seven miRNAs (miR-10b, -21, -125b, -145, -
155, -191, and -382) were found to be up-regulated in breast cancer
patients, and were validated using receiver operating characteristic
(ROC) curves to determine the specificity and sensitivity. Analysis
showed that only three of these miRNAs were found to be related
to breast cancer progression (56). In addition, miR-210 was found
to be strongly increased in the serum of patients with circulating
tumor cells, in metastatic breast cancer (57). Conversely, another
study demonstrated a reduction in circulating miRNAs in cancer
patients (58). In plasma vesicles of lung cancer patients, Silva et al.
(58) observed a reduction in let-7f, miR-20b, and miR-30e-3p.
Let-7f and miR-30e-3p levels facilitating the distinction between
different lung cancer stages, suggesting that they may be prognostic
biomarkers.
Circulating miRNAs may also discriminate between patients
with and without metastasis. For example, in breast cancer, miR-
10b, -34a, and -155 correlate with the presence of metastases (59).
In addition, in prostate cancer, five miRNAs (miR-375, -9*, -
141, -200b, and -516a-3p) are associated with the incidence of
metastases (60).
miRNA PROFILE IN DIFFERENT RENAL CELL CARCINOMA
SUBTYPES
Renal cell carcinoma (RCC) is a frequent form of urologic tumor,
and represents 3% of total human cancers, with a high index of
relapse and a mortality rate of over 40%. During the last 30 years,
the incidence of RCC has increased globally, and has became
the seventh most common carcinoma in men and the eighth
most common in women in the USA (61). RCC is composed
of many different subtypes such as clear cell, papillary, chromo-
phobe, and collecting duct carcinomas (62), which differ in their
clinical outcome and biological features. The majority (75–80%)
of renal tumors are clear cell RCC (ccRCC). This cancer type is
highly vascularized due to mutation or hypermethylation of the
onco-suppressor gene, Von-Hippel–Lindau (VHL). Alteration of
the VHL protein causes constitutive activation of the angiogenic
process, by means of HIF1/HIF2 gene regulation (63).
The correct diagnosis for each type of RCC is fundamental for
the outcome of the patient because each subtype behaves differ-
ently in terms of prognosis and response to treatment. Traditional
diagnostic approaches, based on the histopathological profiles,
have been improved with innovative techniques. These include
the development of new biomarkers that could discriminate
tumor from normal tissue and identify tumor subtypes. In this
contest, miRNA expression profile may provide new diagnostic
approaches (64, 65).
Lu et al. (66) demonstrated the possibility to use miRNAs for
the identification of human cancers with higher accuracy com-
pared with mRNAs, suggesting miRNAs as good candidates as
biomarkers. Whereas miRNAs allowed classification of poorly dif-
ferentiated tumors, mRNA profile did not (66). Recently Youssef
et al. (67) developed a classification able to discriminate the dif-
ferent RCC subtypes, by comparison of relative expression of
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specific miRNA pairs in a four-step decision tree. They analyzed 94
different cases of freshly frozen tissues by microarray and identified
15 differentially expressed miRNAs (miR-126, -192, -194, -200b,
-221, -222, -182, -548m, -183, -663, -22, -498, -25, -200c, -21).
Hierarchic clustering showed similarity between ccRCC and pap-
illary RCC (pRCC) and difference of ccRCC and pRCC in respect
to oncocytoma and chromophobe RCC (chRCC). This system pro-
vided 97% sensitivity to discriminate normal from RCC and 100%
sensitivity to distinguish different RCC subtypes. Similar results
have been described by other groups (64, 68). In particular, the
increased level of miR-200b in chRCC compared with oncocytoma
was also found by Petillo et al. (68). A similar methodology, using
a miRNA marker algorithm, was used by Fridman et al. (64) to
classify RCC, with an accuracy of 90% compared with traditional
diagnosis. In this study, the authors reported an up-regulation
of miR-221 in chRCC and oncocytoma and not in ccRCC and
pRCC (64).
ALTERATION OF miRNA EXPRESSION LEVELS IN RCC
The comparison of the expression levels of miRNAs in RCC with
those of normal kidneys was evaluated in many studies, leading to
the generation of a list of down-regulated and up-regulated miR-
NAs (Figure 1). Up-regulated miRNAs include miR-210, -155, -21,
-142-3p, -185, -34, and -224, which function by down-regulating
tumor suppressor genes (69). miR-210 and -155 instead are known
to be related to HIF molecules and hypoxia (70). On the other
hand, the list of down-regulated miRNAs includes miR-149, -200c,
and -141, the loss of which leads to activation of oncogenes (69).
In particular, miR-141 and -200c are members of the miR-200
family, which are often switched off in different tumors, and are
associated with the EMT (71).
Hidaka et al. (72) focused the attention on down-regulated
miRNAs in RCC and generated a list of 103 miRNAs. By a func-
tional approach, 14 miRNAs were validated as tumor suppressors
in RCC (miR-1285, -206, -1, -135a, -429, -200c, -1291, -133b,
-508-3p, -362-3p, -509-5p, -218, -335, -1255b, and -141) (72).
Some of them (miR-1-1/-133a-2, miR-1-2/-133a-1, and miR-206/-
133b) were found in specific chromosomal regions of human
genome, known to be often down-regulated in different human
cancers (72).
Many molecules involved in the progression of RCCs, such as
HIF, VHL, VEGF, or mammalian target of rapamycin (mTOR),
are possible targets for de-regulated miRNAs (73). Therefore, sev-
eral studies have focused on the biological implication of up- or
down-regulated miRNAs in RCC.
miR-21 is a tumorigenic miRNA, involved in the progression
and in metastasization of many solid tumors as we described
above. Recently, a genomic study on ccRCC defined by the Can-
cer Genome Atlas, demonstrated the correlation of miR-21 with a
worst survival and the connection with a shift toward a “Warburg
effect”-like state. In fact, a decreased methylation on the promoter
of miR-21 (that means higher expression) was highlighted being
clearly associated with worst outcome (74). Moreover, miR-21
expression was induced by high glucose levels and was able to
down-regulate PTEN (18). In addition, increased expression of
miR-21 has been shown to alter the expression of many proteins
involved in tumor invasion (18).
Zaman et al. (75) demonstrated that also miR-23-3p is an
oncogenic miRNA targeting PTEN and its expression level was
increased in RCC. Wang et al. showed a correlation of miR-100 up-
regulation with poor prognosis in RCC patients (76). Conversely,
suppression of miR-205 has been described as being associated
with activation of the ERK1/2 pathway and of FAK and STAT3 pro-
teins (77). Of particular interest, miR-1285 has been identified as
a tumor-suppressor-miRNA. When restored in renal tumor cells,
miR-1285 significantly inhibited cell proliferation, invasion, and
migration (72). Hikada and colleagues demonstrated that transg-
lutaminase 2 (TGM2) is one of the targets of miR-1285. Increased
expression of TGM2 has been shown in many tumors and has been
correlated with EMT, drug resistance, and metastasis (72).
Another important example of down-regulation of tumor-
suppressor-miRNAs is miR-138 that targets vimentin (78).
Vimentin participates to cancer cell migration, metastasis, and
invasion and it is overexpressed in human specimens of RCC.
In addition, the positive staining for vimentin in combination
with CD9 has been proposed as a marker to distinguish ccRCC
and chRCC (79). The significant decrease of miR-138 was also
highlighted, by Girgis et al. (80) who performed an integrated
analysis of copy number, gene expression (mRNAs and miRNAs),
protein expression, and methylation changes in ccRCC. miR-138
is located on the 3p arm, a region that is the most frequently
deleted in ccRCCs. Other important examples of down-regulation
of tumor-suppressor-miRNAs are the reduced expression of miR-
143 and -145, which target hexokinase-2 (81). miR-99a is down-
regulated in several human malignancies. Cui et al. (82) evaluated
its expression and its role in RCC by RT-PCR, demonstrating
that the level of miR-99a was significantly decreased in tumor
samples compared with adjacent tissues. In addition, low expres-
sion level of miR-99a was correlated with poor survival of RCC
patients. The restoration of miR-99a on renal cancer cell lines sup-
pressed tumorigenic properties of cells mainly arresting them in
G1-phase in vitro. Intra-tumoral delivery of synthetic miRNA,
in an in vivo model of human tumor, was shown to block
tumor progression. The target of miR-99a is the mTOR, a mol-
ecule often activated and altered during cancer progression and
metastasis (82).
METASTASIS IN RCC AND miRNA PROFILE
The presence of metastasis in RCC patients is associated with
a mortality of 90% (83). Analysis of the miRNA signature in
metastatic RCC compared with primary RCC showed a signifi-
cant reduction in miR-192, -194, and -215 (Figure 1). Targets of
these miRNAs are ZEB2 and MDM2, molecules associated with
the EMT (83). In addition, miR-200c, which targets ZEB1, is
markedly decreased in metastatic RCC (84). Wotschofsky et al.
(85), by comparing the miRNA expression profile of primary
ccRCC with metastasis, generated a list of 30 down-regulated
miRNAs in metastatic ccRCC, which have thus been defined as
metastamirs (Figure 1). The aim of this study was to evaluate the
differential expression of miRNAs among normal, primary tumor,
and metastatic tissue using microarray screening and subsequent
validation by RT-PCR (85). A parallel study, demonstrated a corre-
lation between a specific miRNA signature and early tumor relapse
after nephrectomy (65). Sixty-four miRNAs have been found to
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FIGURE 1 | De-regulated miRNAs in RCCs. Schematic representation of up-
and down-regulated miRNAs in primary and metastatic RCCs and in serum of
RCC patients. miRNA profile has been suggested as a new accurate method
for the identification of human cancer stages and subtypes. Screening of
miRNAs in RCC samples in respect to normal kidney identified groups of
oncogenic miRNAs (in blue), which act via down-regulation of tumor
suppressor genes and anti-tumor miRNAs (in yellow), which target
onco-proteins. miRNAs have been also correlated to the metastasization
process. miRNA signature in metastatic RCC samples compared with primary
RCC showed a significant reduction of some miRNAs (in yellow), targeting
molecules involved in the EMT transition and invasion. miRNAs have been
detected in serum of RCC patients, supporting their suitability as biomarkers.
be differentially expressed between relapse-free RCC patients and
RCC patients who developed relapse. The expression level of miR-
143, -26a, -145, -10b, -195, and -126 was low in tumors from
patients who developed relapse and in primary metastasis. For
this reason, miR-145, -126, and -127-3p have been proposed as
biomarkers for relapse-free survival (65). Some of these miR-
NAs, such as miR-143, -145, and -26a have been described as
tumor-suppressor-miRNAs in many human tumors (65). The
same approach was used by Wu et al. (86) with the aim to identify a
miRNA signature to predict the risk of metastasis. The expression
level of miR-10b, -139-5p, -130b, and -199b-5p was altered in pri-
mary ccRCC and correlated with the status of ccRCC metastasis.
Thus, these miRNAs have been proposed as prognostic factors for
the development of metastasis (86).
PROFILE OF CIRCULATING miRNAs IN RENAL CELL
CARCINOMA
Only few studies have investigated circulating levels of miRNAs in
RCC (Table 1). In some of these studies, the authors compared
the miRNA expression profile in serum samples with that of tis-
sues (Figure 1). Wulfken et al. (87) observed the up-regulation of
109 miRNAs in serum samples of RCC patients, 36 of which were
present at high levels both in tissue and serum samples. Among
the validated miRNAs, the authors proposed miR-1233 as a RCC
marker that provides 77% sensitivity but only 37.6% specificity.
Redova et al. (88) described 30 miRNAs differentially expressed
in the serum of RCC patients with respect to healthy controls; of
which 19 miRNAs were up-regulated and 11 miRNAs were down-
regulated. Two of these miRNAs have been successfully validated
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Table 1 | Circulating miRNAs in RCC.
miRNAs Sample sources Analysis method Normalization method Reference
miR-1233 RCC serum vs. RCC tissue TaqMan low density array cel-miR-39 Wulfken et al. (87)
miR-378 RCC serum vs. healthy control TaqMan low density array miR-16 Redova et al. (88)
miR-451
miR-378 RCC serum vs. healthy control TaqMan low density array cel-miR-39 Hauser et al. (89)
miR-210 RCC serum vs. RCC tissue qPCR 5s rRNA Zhao et al. (90)
miR-15a Urine qPCR β-actin von Brandenstein et al. (93)
as potential biomarkers, namely miR-378, which is increased, and
miR-451, which is decreased, in the serum of RCC patients. At
variance to these results, in a recent paper, the attempt to validate
miR-378 in the serum of ccRCC patients failed. This particular
study concludes that miR-378 is not able to discriminate between
RCC patients and control subjects (89). Possible explanations for
these differences in study results could be the sample source and
storage as well as the processing and selection of internal controls.
The up-regulation of HIF, due to mutation of VHL, directly
regulates miR-210 expression. Zhao et al. (90) recently proposed
miR-210 as a novel biomarker for RCC. They observed that miR-
210 was expressed at high levels in RCC serum, but decreased
7 days after surgery.
Finally, Teixeira et al. (91) correlated the expression levels
of circulating miR-221/222 and the patients’ overall survival.
High levels of miR-221 have been associated with metastasis and
with a significant reduction of overall survival. Based on these
results, miR-221 has been proposed as potential biomarker of RCC
progression (91).
Urine is another bio-fluid suitable for investigating RCC bio-
markers (92). Only one study describes miRNAs as biomarkers in
urine of RCC patients. von Brandenstein et al. (93) observed an
up-regulation of miR-15a in the urine of RCC patients compared
with healthy subjects. The expression of miR-15a is regulated by
PKC, which blocks the release of the primary miRNA by direct
binding. The expression pattern of PKC isoforms differs between
RCC and benign oncocytoma; in fact, PKC is up-regulated in
benign oncocytoma but down-regulated in RCC. Conversely, miR-
15a is up-regulated in RCC and down-regulated in oncocytoma
suggesting that this miRNA may be a marker of ccRCCs (93).
In RCC, a small population of cells expressing the mesenchymal
stem cell marker CD105 has been identified as CSCs. This popu-
lation grows as spheres, possesses clonogenic ability, and expresses
Nestin, Nanog, and Oct-3/4 stem cell markers (94). CD105+ renal
CSCs show the unique ability to generate serially transplantable
tumors in vivo that resemble the tumor of origin (94). We found
that EVs derived from CD105+ renal CSCs may modify the tumor
microenvironment. These EVs, at variance to those derived from
differentiated tumor cells, are able to trigger angiogenesis and to
induce the formation of a pre-metastatic niche in the lung (95).
Comparison of RNAs present inside these two different types
of vesicles showed the enrichment of transcripts coding for sev-
eral pro-angiogenic proteins such as VEGF, FGF, angiopoietin 1,
ephrin A3, MMP2, and MMP9 in EVs derived from CSCs. The
miRNA expression profile of EVs released from CSCs and differ-
entiated tumor cells was also compared. This analysis revealed the
presence of 24 significantly up-regulated miRNAs and 33 down-
regulated miRNAs in CSC-derived EVs (95). Prediction for targets
of miRNA that are enriched in CSC-derived EVs by gene ontology
analysis, illustrated a strong over-representation of crucial bio-
logical processes like transcription, metabolic processes, nucleic
acid binding, cell adhesion molecules, and regulation of cell pro-
liferation. Among the miRNAs shuttled by CSC-derived EVs, we
detected miR-200c, -92, and -141, which have been described as
significantly up-regulated in patients with ovarian, colorectal, and
prostate cancer, respectively (95). In addition, miR-29a, -650, and
-151 were associated with tumor invasion and metastases (96–98).
Moreover, the enrichment of miR-19b, -29c, and -151 has been
described as being directly associated with RCC (99).
miRNA TARGETING AND THERAPY
The evidence that some miRNAs are commonly de-regulated in
many human cancer leads to the hypothesis to exploit them as
new therapeutic targets. The inhibition of oncogenic miRNAs is a
promising approach that can be achieved through siRNA- or anti-
sense oligonucleotide-based therapy (100). This strategy has been
set up in different xenograft tumor models; for example, an anti-
sense oligonucleotide targeting miR-21 has been successfully used
in vitro and in vivo in a breast cancer model (101). Kim et al. (102)
used a miRNA-221 molecular beacon (miR-221-MB)-conjugated
magnetic/fluorescence nanoparticle probe as a cancer-targeting
theranostic dye (MFAS-miR-221-MB) to simultaneously follow
localization and inhibition of miR-221 in thyroid cancer.
Another approach used to decrease the level of oncomiRNAs is
the use of miRNA sponges. This strategy consists in cloning mul-
tiple copies of a specific sequence, complementary to a selected
miRNA. miRNA sponges, once transfected into tumor cells, com-
pete with the natural target for miRNA binding. Using this tech-
nique, Ma et al. (103) demonstrated a reduction of invasiveness of
a breast cancer cell line using a sponge trapping miR-9.
On the other hand, tumor-suppressor miRNAs are usually
down-regulated in cancer and the administration of synthetic
miRNAs may be a therapeutic option. This strategy is based on
the replacement of the under-represented miRNAs in the tumor.
For example, the tumor suppressor let-7 has been injected intra-
tumor in a mouse model of non-small cell lung cancer leading to
the reduction of tumor size. Another miRNA often de-regulated
in different cancers is miR-34. Recently, a miRNA-based formu-
lation (MRX34) has entered in a clinical trial for hepatocellular
carcinoma treatment. MRX34 is a liposomal nanoparticle loaded
with a synthetic mimic of the tumor suppressor miR-34. In pre-
clinical animal models, systemic administration of MRX34 has
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Table 2 | Prognostic biomarkers for RCC.
Primary tumor Metastasis Poor overall survival
miRNA Biological sample miRNA Biological sample miRNA Biological sample
miR-210 (90) Serum miR-221 (91) Serum miR-221 (91) Serum
miR-210 (69) Tumor tissue miR-10b, -139-5p, -130b, -199-5p (86) Primary tumor tissue miR-100 (76) Tumor tissue
miR-21 (106) Tumor tissue miR-21 (74) Tumor tissue
been shown to inhibit the growth of primary tumors, to block
metastasis, and to extend survival (104).
CONCLUSION
The presence of selected patterns of oncogenic miRNAs may be
used as diagnostic and prognostic tool. The use of biological fluids
such as serum, plasma, or urine may allow to perform non-invasive
analysis. Circulating miRNAs are derived from different tumor
populations (cancer cells, tumor-surrounding cells, and CSCs) and
they could be also influenced by stages and progression of cancer.
The studies of miRNAs that are present in biological fluids and
tissues have generated contrasting results according to technical
procedures and analysis methods. One of the main problems is
the stability of miRNAs in biological fluids due to the presence of
degradative enzymes. Recent observations that EVs derived from
tumor cells contain defined patterns of miRNAs may offer a new
approach for the identification of miRNA biomarkers. In fact,
vesicles are able to confer stability to extracellular RNAs.
Moreover, the heterogeneous sample sources (primary tumor
tissue, metastasis tissue, healthy tissue, and serum) used to com-
pare miRNA expression profile is another variable to take into
account. Also, the choice of appropriate endogenous controls for
data normalization is a relevant limit. The use of synthetic spike-in
controls from C. elegans, such as cel-miR-39, -43, -54, and -238 has
been proposed as an alternative normalizer instead of ubiquitary
expressed miRNAs such as miR-16 or -21 (88, 105).
However, some miRNAs, present in biological samples, have
been proposed as prognostic factors even if, at the moment, they
are not validated in preclinical and clinical setting. Table 2 sum-
marizes candidate miRNAs proposed as prognostic biomarkers
for RCC.
In conclusion, the use of miRNAs as biomarkers in clinical
practice is a potentially powerful tool for non-invasive analysis,
which, at the moment requires further development.
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